|
Harm From Radiotherapy for Colorectal Cancer FROM: The Lancet (March 23) 2002; 359: 1068-69. Preoperative and Postoperative radiotherapy and survival in colorectal cancer Sir--The Colorectal
Cancer Collaborative Group1 clearly show that neither
preoperative nor postoperative radiation therapy has an appreciable
effect on overall survival in patients with this disease. Patients who
received postoperative radiation therapy did have a 9% lower risk of
death from rectal cancer than controls. But this survival advantage
was all but wiped out by the more frequent deaths from other causes in
the radiation therapy group. Overall, the risk of death from causes
other than rectal cancer was 15% higher in those who received
radiation therapy than in those who did not, a significant difference.
The Collaborative
Group state that there was no clear benefit of radiotherapy for
overall survival. Yet, B Minsky, in his Oct 20 commentary,2
believes that the study results support the use of adjuvant radiation
therapy for rectal cancer. That conclusion arises because preoperative
radiation therapy did decrease the chance of a recurrence at 5 years
by 7%. The Collaborative Group also believe that since uncontrolled
local recurrence can have a devastating effect on patients' quality of
life, improved local control with radiotherapy might be a sufficient
benefit to justify this treatment's use. Yes, uncontrolled
local recurrences are devastating. But so too are excess deaths caused
by radiation therapy, such as through cardiovascular disease,
infections, and other, unknown, causes. The researchers and Minsky do
not mention that the side-effects to the bowel of radiation therapy
can devastate patients' quality of life. Patients receiving radiation
therapy for rectal cancer have more chronic bowel dysfunction than do
those who undergo surgical resection alone.3 Diarrhoea,
bleeding, tenesmus, and pain on defecation are frequent during
therapy. These symptoms
commonly subside when treatment stops. However, 6 months to 1 year or
more later, delayed postradiation symptoms can develop. In one
textbook these symptoms are described: "There may be two to four
or even eight or more bowel movements a day, and the urgency may be
compelling. Blood is also often seen. Tenesmus is frequent, and
cramping pain is often associated with defecation. Radiation proctitis
frequently is associated with pain and bleeding; the latter may be
severe and persistent, occasionally requiring transfusions . . .
Severe or complete obstruction may develop."4 Any assessment of
radiation therapy must take into account not just the statistical
effect of treatment on recurrences, but what patients actually
experience as a result of the treatment. What patients and their
families need is the complete picture, of costs as well as benefits,
without which it is impossible for them to make educated treatment
decisions. But how many rectal cancer patients, I wonder, are told
that adjuvant radiation therapy has not been proven to extend life but
may in fact cause serious short-term and long-term adverse effects?
How many are told that adjuvant radiation may in fact lead to their
untimely deaths? Ralph W Moss The Moss
Reports, PO Box 8183, State College, PA 16803, USA (e-mail:moss@cancerdecisions.com)
1 Colorectal Cancer
Collaborative Group. Adjuvant radiotherapy for rectal cancer: a
systematic overview of 8507 patients from 22 randomised trials. Lancet
2001; 358: 1291-304. [Text]
2 Minsky BD.
Adjuvant radiation therapy for rectal cancer: is there finally an
answer? Lancet 2001; 358: 1285-86. [Text]
3 Kollmorgen CE,
Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM. The
long-term effect of adjuvant postoperative chemoradiotherapy for
rectal carcinoma on bowel function. Ann Surg 1994; 1220:
676-82. 4 Fajardo LF,
Berthrong M, Anderson RE. Radiation Pathology. Oxford: Oxford
University Press, 2001: 244-45. Authors' reply
…….. We agree with Ralph
Moss that the benefits of radiotherapy in preventing recurrence and
death from rectal cancer need to be balanced against short-term and
long-term adverse effects. However, we believe that the available data
suggest that the benefits from adding radiotherapy to surgery for
rectal cancer probably outweigh the negative consequences for many
patients. Radiotherapy, at adequate preoperative doses, significantly
improved overall survival, even though some of the included trials
used outdated--and hazardous--radiation techniques. Thus, although an
extension of life has not been the primary aim of radiotherapy, modern
techniques that deliver radiotherapy more accurately will probably
produce a net survival benefit. Long-term follow-up of late effects in
recent trials is needed to be sure, but adverse effects on quality of
life so far seem mild.1,2 Finally, we believe
that most patients offered radiotherapy for rectal cancer are
adequately informed about the potential negative consequences as well
as the established benefits. It would not be helpful to list the
postradiation symptoms cited by Moss, however, since they are hardly
ever seen with the doses used to kill microscopic disease that might
be left after apparently curative rectal cancer surgery. *Richard Gray,
Bengt Glimelius, Robert Hills, Joanna Marro, Rebecca Stowe, for the
Colorectal Cancer Collaborative Group Birmingham
Clinical Trials Unit, Park Grange, Edgbaston, Birmingham B15 2RR, UK
(e-mail:R.Gray@bham.ac.uk)
1
Glimelius B, Isacsson U. Preoperative radiotherapy for rectal
cancer--is 5x5 Gy good or a bad schedule? Acta Oncol 2001; 40: 958-67. [PubMed]
2
Marijnen CAM, Kapiteijn E, van de Velde CJH, et al. Acute side-effects
and complications after short-term preoperative radiotherapy combined
with total mesorectal excision in primary rectal cancer: report of a
multicenter randomized trial. J Clin Oncol 2002; 20: 817-25. [PubMed] |